Tags

Type your tag names separated by a space and hit enter

Local recurrence after breast-conserving therapy for phyllodes tumors: A 15-year retrospective review.
Breast J 2019BJ

Abstract

There are few data on the long-term outcomes of patients with phyllodes tumors following breast-conserving surgery with or without radiation therapy (RT). We reviewed 69 patients diagnosed from 2000 to 2015 with surgical specimens available for central pathology assessment for outcome in relation to histopathologic subtype, margin width, and utilization of RT. Median follow-up was 63 months (interquartile range, 35-131 months). Forty-eight patients had benign, 13 borderline, and eight malignant phyllodes tumors, with local recurrence rates of 4%, 0%, and 38%, respectively (P ≤ .04 comparing malignant lesions to both benign and borderline lesions). None of the eight patients who received RT suffered a local recurrence. Two of the 26 (8%) patients with benign phyllodes tumors who did not receive RT with margins that were positive or <1 mm had local recurrence, compared to none of 18 patients with margins 1 mm or wider who did not receive RT. The one patient with a malignant phyllodes tumor who did not receive RT with margins that were positive or <1 mm did not locally recur, while both patients with margins 10 mm or wider who did not receive RT had local recurrence. One patient with a malignant phyllodes tumor developed distant recurrence following local recurrence. Phyllodes histologic type and margin width were both associated with the risk of local recurrence following breast-conserving surgery without RT, though the number of events and patients was too small to show these trends were statistically significant.

Authors+Show Affiliations

Department of Surgery, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.Department of Obstetrics and Gynecology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.Department of Obstetrics and Gynecology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.Departments of Radiation Oncology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA. Department of Pathology, Brigham & Women's Hospital, Boston, MA, USA.Department of Obstetrics and Gynecology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA. Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, MA, USA.Department of Surgery, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA. Department of Surgery, SUNY Upstate Medical University, Syracuse, NY, USA.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

31814215

Citation

Cervoni, Gabrielle E., et al. "Local Recurrence After Breast-conserving Therapy for Phyllodes Tumors: a 15-year Retrospective Review." The Breast Journal, 2019.
Cervoni GE, Quintana L, Erlinger AL, et al. Local recurrence after breast-conserving therapy for phyllodes tumors: A 15-year retrospective review. Breast J. 2019.
Cervoni, G. E., Quintana, L., Erlinger, A. L., Neo, D. T., Recht, A., Schnitt, S. J., ... Sharma, R. (2019). Local recurrence after breast-conserving therapy for phyllodes tumors: A 15-year retrospective review. The Breast Journal, doi:10.1111/tbj.13707.
Cervoni GE, et al. Local Recurrence After Breast-conserving Therapy for Phyllodes Tumors: a 15-year Retrospective Review. Breast J. 2019 Dec 9; PubMed PMID: 31814215.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Local recurrence after breast-conserving therapy for phyllodes tumors: A 15-year retrospective review. AU - Cervoni,Gabrielle E, AU - Quintana,Liza, AU - Erlinger,Adrienne L, AU - Neo,Dayna T, AU - Recht,Abram, AU - Schnitt,Stuart J, AU - Hacker,Michele R, AU - Sharma,Ranjna, Y1 - 2019/12/09/ PY - 2019/08/18/received PY - 2019/11/20/revised PY - 2019/11/21/accepted PY - 2019/12/10/entrez PY - 2019/12/10/pubmed PY - 2019/12/10/medline KW - breast cancer KW - breast tumor KW - fibroepithelial tumor KW - phyllodes tumor of the breast JF - The breast journal JO - Breast J N2 - There are few data on the long-term outcomes of patients with phyllodes tumors following breast-conserving surgery with or without radiation therapy (RT). We reviewed 69 patients diagnosed from 2000 to 2015 with surgical specimens available for central pathology assessment for outcome in relation to histopathologic subtype, margin width, and utilization of RT. Median follow-up was 63 months (interquartile range, 35-131 months). Forty-eight patients had benign, 13 borderline, and eight malignant phyllodes tumors, with local recurrence rates of 4%, 0%, and 38%, respectively (P ≤ .04 comparing malignant lesions to both benign and borderline lesions). None of the eight patients who received RT suffered a local recurrence. Two of the 26 (8%) patients with benign phyllodes tumors who did not receive RT with margins that were positive or <1 mm had local recurrence, compared to none of 18 patients with margins 1 mm or wider who did not receive RT. The one patient with a malignant phyllodes tumor who did not receive RT with margins that were positive or <1 mm did not locally recur, while both patients with margins 10 mm or wider who did not receive RT had local recurrence. One patient with a malignant phyllodes tumor developed distant recurrence following local recurrence. Phyllodes histologic type and margin width were both associated with the risk of local recurrence following breast-conserving surgery without RT, though the number of events and patients was too small to show these trends were statistically significant. SN - 1524-4741 UR - https://www.unboundmedicine.com/medline/citation/31814215/Local_recurrence_after_breast-conserving_therapy_for_phyllodes_tumors:_A_15-year_retrospective_review L2 - https://doi.org/10.1111/tbj.13707 DB - PRIME DP - Unbound Medicine ER -